Heron Therapeutics logo

Heron TherapeuticsNASDAQ: HRTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 August 1987

Next earnings report:

12 November 2024

Last dividends:

N/A

Next dividends:

N/A
$269.82 M
-78%vs. 3y high
57%vs. sector
-vs. 3y high
-vs. sector
-124%vs. 3y high
5%vs. sector
-86%vs. 3y high
37%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:17:28 GMT
$1.78-$0.00(-0.06%)

Dividend

No data over the past 3 years
$36.02 M$36.62 M
$36.02 M-$9.23 M

Analysts recommendations

Institutional Ownership

HRTX Latest News

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
prnewswire.com29 October 2024 Sentiment: POSITIVE

SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
prnewswire.com10 October 2024 Sentiment: POSITIVE

SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not require additional dilution with IV fluids in what may be a time of critical shortage.

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
prnewswire.com25 September 2024 Sentiment: POSITIVE

- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
prnewswire.com30 July 2024 Sentiment: POSITIVE

SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights.

Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
zacks.com11 July 2024 Sentiment: POSITIVE

Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
prnewswire.com02 July 2024 Sentiment: POSITIVE

-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
prnewswire.com29 May 2024 Sentiment: POSITIVE

SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion of the FDA's review of this PAS within the next several weeks and anticipates an action date on this PAS to be between four (4) and six (6) months.

What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
zacks.com21 May 2024 Sentiment: POSITIVE

Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • 1(current)

What type of business is Heron Therapeutics?

Heron Therapeutics, Inc. is a commercial biotechnology company focused on improving the lives of patients by developing new methods of treating post-operative pain and cancer. Products SUSTOL and CINVANTI have been developed for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy, these two drugs have been approved and are already being marketed by the Company. HTX-011 for the treatment of post-operative pain is awaiting FDA approval. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

What sector is Heron Therapeutics in?

Heron Therapeutics is in the Healthcare sector

What industry is Heron Therapeutics in?

Heron Therapeutics is in the Biotechnology industry

What country is Heron Therapeutics from?

Heron Therapeutics is headquartered in United States

When did Heron Therapeutics go public?

Heron Therapeutics initial public offering (IPO) was on 26 August 1987

What is Heron Therapeutics website?

https://www.herontx.com

Is Heron Therapeutics in the S&P 500?

No, Heron Therapeutics is not included in the S&P 500 index

Is Heron Therapeutics in the NASDAQ 100?

No, Heron Therapeutics is not included in the NASDAQ 100 index

Is Heron Therapeutics in the Dow Jones?

No, Heron Therapeutics is not included in the Dow Jones index

When was Heron Therapeutics the previous earnings report?

No data

When does Heron Therapeutics earnings report?

The next expected earnings date for Heron Therapeutics is 12 November 2024